Oncimmune Holdings plc
ONC.L · LSE
8/31/2024 | 2/29/2024 | 8/31/2023 | 2/28/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| FCF Yield | -9.27% | -13.70% | -22.98% | -11.66% |
| EV / EBITDA | -7.38 | -33.60 | -26.21 | -12.55 |
| Quality | ||||
| ROIC | -50.84% | -18.80% | -15.47% | -53.50% |
| Gross Margin | 49.90% | 38.45% | 100.00% | 30.60% |
| Cash Conversion Ratio | 0.50 | 1.98 | 1.88 | 0.70 |
| Growth | ||||
| Revenue 3-Year CAGR | 72.09% | 90.80% | 111.72% | 146.23% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -1.83 | -7.20 | -2.84 | -3.53 |
| Interest Coverage | -5.90 | -2.18 | -0.71 | -6.07 |
| Efficiency | ||||
| Inventory Turnover | 3.27 | 2.03 | 0.00 | 1.99 |
| Cash Conversion Cycle | 45.70 | -25.78 | 0.00 | -61.85 |